US Edition
GLP-1 Drugs May Be Linked to Elevated Risk of Serious Eye Disease, Study Finds
- Researchers from Ontario, Canada, published a study on June 5, 2025, linking GLP-1 drugs to an increased risk of serious eye disease in older adults.
- The study analyzed health records of 139,002 patients aged 66 or older from 2020 to 2023, comparing GLP-1 users with non-users matched on demographics and conditions.
- The study found that individuals using GLP-1 receptor agonists had more than double the risk of developing the neovascular form of age-related macular degeneration compared to non-users, with a hazard ratio of 2.21; however, the overall occurrence remained low at 0.2%.
- Co-Author Reut Shor noted, "Seeing such a clear signal in our study was striking," while experts emphasized the study does not prove causality but urges careful monitoring.
- The findings suggest the need for further clinical studies to clarify causality and recommend greater awareness among prescribing physicians regarding potential ocular adverse events.
21 Articles
21 Articles
The European Medicines Agency (EMA) has warned that patients taking weight loss and diabetes drugs, including Ozempic and Wegovy, have an increased risk of developing a rare eye disease that can cause vision loss.
Shafaq News/ The British newspaper, The Guardian, reported that a large-scale study has found that weight-loss drugs may at least double the risk of diabetes patients developing age-related macular degeneration. According to the newspaper, glucagon-like peptide-1 receptor agonists (GLP-1 RA) were originally developed for diabetics and have transformed the treatment of obesity. There is growing evidence of their health benefits, as they help lowe…
They Lost 23 Kilos: Study Discovers a Drug that Exceeds Ozempic and Is More Effective to Lose Weight
For years, Ozempic and its active semaglutide compound have been the star element of injectable weight-loss drugs. But a new research published in the New England Journal of Medicine has just changed the picture: tirzepatide, marketed as Zepbound, is more effective than Ozempic and Wegovy in combating obesity.The study directly compared the effects of both drugs over a 72-week period.
What It Really Means to Microdose Ozempic
Just when we think we've reached the peak of GLP-1 news — more comes in. This time, a topic once confined to the shadowy alleyways of Ozempic Reddit threads has officially gone mainstream: patients are "microdosing" the weight-loss medications. Sure, there've been whispers of Hollywood celebrities using it to get red carpet ready, but now it's something many people are opening up about. In the context of GLP-1 medications like Ozempic and WeGovy…
Coverage Details
Bias Distribution
- 71% of the sources lean Left
To view factuality data please Upgrade to Premium
